TOKYO - A panel at Japan's health ministry refused to approve on Wednesday a new Alzheimer's disease drug jointly developed by Japan's Eisai Co. and U.S. firm Biogen Inc., saying more data are needed to judge its effectiveness.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
